2026

ABCSG 66 / ADAPTela: First Site Activated and First Patient Enrolled

02.09.2026

The ABCSG is pleased to announce that the first Austrian site has been activated for the ABCSG 66 / ADAPTela trial, where the first patient has also been enrolled.

The Department of Gynecology at the Medical University of Innsbruck, under the leadership of Dr. Daniel Egle, was activated for patient enrollment on August 21, 2026. This marks the official launch of the study in Austria.

Enrollment target reached for the ABCSG 55N / AMBHER study

10.08.2026

The non-interventional ABCSG 55N / AMBHER study has reached an important milestone: The enrollment target of 500 patients was achieved in July 2026. Following the last patient inclusion on August 3, 2026, the study population comprises a total of 501 patients.

Editorial by Professor Michael Gnant published in Cancer Biology & Medicine

15.04.2026

We are pleased to share a recent editorial by ABCSG President Professor Michael Gnant, who was invited to present his assessments on the evolving landscape of breast cancer care in Cancer Biology & Medicine.

Share on